Budesonide/glycopyrronium bromide/formoterol

Budesonide/glycopyrronium bromide/formoterol (BGF) is a fixed-dose combination medication used in the management of chronic obstructive pulmonary disease (COPD). It contains three active ingredients: budesonide, a corticosteroid; glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA); and formoterol, a long-acting beta2-adrenergic agonist (LABA).

Etymology

The name of the medication is derived from the names of its three active ingredients: budesonide, glycopyrronium bromide, and formoterol.

Pharmacology

Budesonide is a corticosteroid that reduces inflammation in the lungs. Glycopyrronium bromide is a muscarinic antagonist that dilates the airways, and formoterol is a beta2-adrenergic agonist that relaxes the muscles of the airways. Together, these three drugs help to improve breathing in people with COPD.

Indications

BGF is indicated for the maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.

Contraindications

BGF is contraindicated in patients with a hypersensitivity to budesonide, glycopyrronium bromide, formoterol, or any of the ingredients in the formulation. It is also contraindicated in patients with asthma without use of a long-term asthma control medication.

Side Effects

Common side effects of BGF include upper respiratory tract infection, pneumonia, bronchitis, oral candidiasis, back pain, and cough. Serious side effects may include worsening of COPD, pneumonia, and osteoporosis.

Interactions

BGF may interact with other drugs, including beta-blockers, diuretics, anticholinergics, and other bronchodilators. It is important to tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

See Also

• Chronic obstructive pulmonary disease
• Budesonide
• Glycopyrronium bromide
• Formoterol